Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + Binimetinib +/- Ribociclib in BRAF V600 Solid Tumors
NCT01543698Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2012
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of encorafenib, binimetinib in solid tumor, melanoma, colorectal cancer (CRC), sponsored by Pfizer. Started May 2012; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
solid tumormelanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01543698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543698.